Literature DB >> 31419354

Key characteristics of basal cell carcinoma with large subclinical extension.

T Greywal1, A Goldenberg1, S Eimpunth2, S B Jiang1.   

Abstract

BACKGROUND: Basal cell carcinoma with large subclinical extension (BCC-LSE) is a tumour whose extensive spread becomes apparent during Mohs surgery histopathology review. Not recognizing BCC-LSE preoperatively may result in a greater number of Mohs layers and in larger than anticipated postoperative defects.
OBJECTIVE: To evaluate the characteristics of BCC-LSE.
METHODS: This retrospective study reviewed BCC treated with Mohs surgery at a single academic surgical centre between March 2007 and February 2012. A total of 2044 cases met the criteria of BCC-LSE, which was defined as a lesion requiring at least three Mohs stages and a final surgical margin (difference between preoperative and postoperative measurements in either vertical or horizontal dimensions) of ≥1 cm.
RESULTS: In adjusted multivariable analysis, male sex (P = 0.05), Fitzpatrick skin type I (P = 0.002), history of prior BCC (P = 0.003) and subtypes of basosquamous, metatypical, micronodular, infiltrative, morpheaform and sclerosing (P = 0.005) remained significant BCC-LSE predictors.
CONCLUSIONS: Demographic factors, including personal history of BCC, skin type, anatomic location, gender and age, in addition to tumour histologic subtype assessed through incisional biopsy, can help predict occurrence of BCC-LSE and assist physicians in optimizing preoperative assessment of surgical time and complexity.
© 2019 European Academy of Dermatology and Venereology.

Entities:  

Year:  2019        PMID: 31419354     DOI: 10.1111/jdv.15884

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  1 in total

1.  Clinicopathological factors influencing the number of stages of Mohs surgery for basal cell carcinoma.

Authors:  Joana Calvão; André Pinho; Ana Brinca; Ricardo Vieira
Journal:  An Bras Dermatol       Date:  2022-04-02       Impact factor: 2.113

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.